Glaucoma 2.0: neuroprotection, neuroregeneration, neuroenhancement.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 22349567.
- Also identified by DOI 10.1016/j.ophtha.2011.11.003 and PMC identifier 3343191.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Glaucoma is a progressive neurodegenerative disease of retinal ganglion cells (RGCs) associated with characteristic axon degeneration in the optic nerve. Clinically, our only method of slowing glaucomatous loss of vision is to reduce intraocular pressure (IOP), but lowering IOP is only partially effective and does not address the underlying susceptibility of RGCs to degeneration. We review the recent steps forward in our understanding of the pathophysiology of glaucoma and discuss how this understanding has given us a next generation of therapeutic targets by which to maintain RGC survival, protect or rebuild RGC connections in the retina and brain, and enhance RGC function.
Medical subject headings
- Glaucoma
- Nerve Regeneration
- Neuroprotective Agents
- Retinal Ganglion Cells